亚洲毛片视频-亚洲毛片免费在线观看-亚洲毛片免费看-亚洲码专区-亚洲码在线-亚洲伦理中文字幕一区

  Tianjin medical equipment chamber of commerce welcomes you.

The contrast agent market under rapid growth

Column:Industry dynamic Time:2019-07-01

The worldwide contrast agent market has matured to a greater extent in recent years. According to the report of MarketsandMarkets, the market of contrast agents was growing at a stable pace. The worldwide market value of contrast agents in 2016 was around 4.45 billion dollars, and was anticipated to reach 5.44 billion dollars in 2021, with a compound annual growth rate of 4.1%. Among the worldwide contrast agent market, the market share of the US is about 34.66%, of the Europe is about 27.83%, and of the China is about 30%. The contrast agent market in China is growing rapidly, with a compound annual growth rate of 11.67% in the past 5 years.

Bright prospect of the iodixanol market

The contrast agents are divided into 4 large types, namely, x-ray CT contrast agents, MRI contrast agents, ultrasound contrast agents and radionuclide contrast agents. According to the statistical data of Chinese Pharmaceutical Association, the sales amount of contrast agents in sample hospitals in 2018 reached CNY 4.237 billion, with a compound annual growth rate of 11.67% in the past 5 years; the sales amount of X-ray CT contrast agents from 2014 to 2018 accounted for 78.45% of the total amount in China (see Figure 1).

X-ray CT contrast agents can be divided into 2 types based on the molecular structure and characteristics: ionic and nonionic contrast agents. The ionic contrast agents have a very small market due to the less satisfactory safety; the nonionic contrast agents, including iohexol, iopamidol, iopromide, ioversol and iodixanol, enjoy a bright development prospect.

The rapid growth of X-ray CT contrast agents is mainly driven by iodixanol, and a stable growth has already been obtained in the sale of iohexol, iopamidol, iopromide and ioversol. The sales amount distribution map of top 5 contrast agents in the sample hospitals from 2014 to 2018 in China showed a significant growth in the sales amount of iodixanol. The iodixanol became the single type of contrast agent with the largest sales amount in 2017 when it exceeded the iohexol (see Figure 2).  

Iodixanol, a type of nonionic dimeric organoiodine contrast agents used with X-ray and CT, applies to intraspinal angiography, cardiovascular angiography and intravenous urography. The data show that iodixanol, isotonic with blood, will improve the tolerance and reduce the risk of serious adverse reaction. In the past several years, the market of iodixanol keeps growing at a fast pace, and we believe that it will become more and more popular.

In 2018, the sales amount of iodixanol in sample hospitals in China reached CNY 1.06 billion, accounting for 24.96% among the domestic contrast agents. A significant growth has been obtained in the sales amount of iodixanol from 2014 to 2018, with a compound annual growth rate of 29.26%, topping the sales amount of domestic contrast agents.

According to the report of MarketsandMarkets, in 2016 the consumption rate of bulk drugs of X-ray contrast agents was 1.49 tons per million users, higher than the average global level. There is still room for growth for it only accounts for 17.45% of the US, and 69.95% of the Europe.

The public data showed that the compound annual growth rate of CT equipment in 2019 was around 10% in China. Due to a large population base in China and high incidence of tumors, cardiovascular and cerebrovascular diseases and urinary system diseases, the X-ray and CT angiography were more widely used in examination. The third-generation nonionic contrast agent odixanol with a relatively high biological safety is expected to maintain its rapid growth momentum.

In 2018, the market value of contrast agents in China was around 1.8 billion dollars, with a compound annual growth rate of 11.67% in the past 5 years. If the grow rate can be maintained, it is expected that the value will exceed 2.25 billion dollars in 2020.

5 enterprises in the market

Currently, there are 5 enterprises competing in the odixanol market in China, 4 from China and 1 from other country (Nycomed, an original drug enterprise, was transferred to GEHealthcare). Among the 5 enterprises, Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. entered the market since June, 2018. By relying on the quality and cheap original drugs provided by Zhejiang Starry Pharmaceutical Co., Ltd., Hengrui Medicine expands its market by its edge in cost performance and localized academic marketing.

According to the data of sample hospitals in China, Hengrui Medicine enjoys the absolute advantage in the iodixanol market. In 2018, Hengrui Medicine’s the sales amount was CNY 624 million, accounting for 58.98% of the total market value, with a compound annual growth rate of 43.21% over the past 5 years. Chances are that the iodixanol may be a hit product with a sales amount over CNY 1 billion in Hengrui Medicine.

Is there a chance for the new enterprises to find their places in the iodixanol market under rapid growth? It depends on whether they can obtain the quality and cheap original drugs.

Zhejiang Starry Pharmaceutical Co., Ltd., a leading enterprise that has been producing and selling the original drugs of contrast agents for over 10 years, is one of the enterprises that own a complete product line concerning the original drugs of contrast agents in China. Its products have been approved in China, the US, EU, Japan and other countries and regions. Hengrui Medicine’s success in the contrast agent market cannot be made without the original drugs provided by Zhejiang Starry Pharmaceutical Co., Ltd.

Low dosage and toxicity is the direction of research and development

Except the X-ray CT contrast agents, ultrasound contrast agents have the smallest market. Hence, it has little value for the enterprises to invest in ultrasound contrast agents.

According to the data of sample hospitals in China, despite of a compound annual growth rate of 39.82%, new enterprises have little chance to find their places in the radionuclide contrast agent market for the raw materials are highly monopolized.

Recently, the market of MRI contrast agents increases rapidly with the growing number of installed MRI equipment and examined patients. In 2018, the market value of MRI contrast agents (gadolinium-based contrast agents) in sample hospitals in China reached CNY 0.52 billion, with a year-on-year growth rate of 21.82% and compound annual growth rate of 11.44% in the past 5 years. It is expected that MRI contrast agents have a bright market prospect to maintain a grow rate of 12%.

Currently, it has been a common sense in the contrast agent study to reduce the toxicity against living bodies by lowering the use of contrast agents. Problems in the clinical use of contrast agents include high dosage, low ability to target tumors and toxic and side effects. Low toxicity, cost, high targeting ability, and satisfactory stability in bodies are the future study trend of contrast agents.

主站蜘蛛池模板: 国产性高清在线观看 | 天天爱天天做天天干 | 一个人看的www日本视频 | 免费精品99久久国产综合精品 | 天天弄天天操 | 日本午夜视频在线观看 | 香蕉网站在线观看影院 | 在线观看福利视频在线观看 | 国产精品v片在线观看不卡 国产精品v一区二区三区 | 日韩 欧美 自拍 在线 视频 | 久久精品欧美一区二区 | 免费特黄一级欧美大片 | 亚洲欧美精品综合中文字幕 | 一区二区三区www | 亚洲a级| 一二三四视频社区在线 | 好吊妞国产欧美高清免费视频 | 一二三四五在线播放免费观看高清 | 亚洲伊人久久大香线蕉影院 | 国产永久在线视频 | 精品在线免费视频 | 日本一区二区在线免费观看 | 日本高清免费视频aa | 日本天堂网 | 成人做爰网站免费看 | 国产三级日本三级美三级 | 交视频在线观看国产网站 | 国产特一级毛片 | 免费成年网站 | 国产成人精品免费影视大全 | 久久不卡一区 | 日本二区在线观看 | 成人久久视频 | 搞黄视频免费看 | 国产一级在线播放 | 久久噜| 国产一区三区二区中文在线 | 日韩美aaa特级毛片 日韩美毛片 | 亚洲一区二区在线播放 | 福利午夜757久久久 福利午夜国产网站在线不卡 | 天天爱天天做天天爽天天躁 |